Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes

Corrigendum to “Healthcare costs of the SATisfaction and adherence to COPD treatment (SAT) study follow-up” (Respiratory Medicine (2019) 153 (68–75), (S0954611119301763), (10.1016/j.rmed.2019.05.017))

The authors regret that the affiliations of two authors were incorrectly reported. The right affiliation of Fabiano di Marco is: “Department of Health Science, University of Milan, Respiratory Unit, Pope John XXIII Hospital, Bergamo, Italy”; the right affiliation of Pierachille Santus is: “Department of Biomedical and Clinical Sciences (DIBIC), University of Milan, Milan, Italy”. The authors would like to apologise for any inconvenience caused.